Novavax, Inc. (NVAX)
Novavax, Inc.
700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1,543
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John Joseph Trizzino B.S., M.B.A. | President & COO | 641.22k | N/A | 1960 |
| Mr. James Patrick Kelly C.F.A. | Executive VP, CFO & Treasurer | 644.32k | N/A | 1966 |
| Mr. Stanley Charles Erck | Advisor | 1.09M | N/A | 1948 |
| Mr. John Charles Jacobs M.B.A. | CEO & Director | N/A | N/A | 1967 |
| Mr. Richard P. Crowley | Executive VP & COO | N/A | N/A | 1957 |
| Mr. Troy Morgan Esq., J.D. | Senior VP & Chief Compliance Officer | N/A | N/A | 1971 |
| Mr. Mark Casey | Executive VP, Chief Legal Officer & Corporate Secretary | N/A | N/A | N/A |
| Ms. Erika S. Trahan | Associate Director of Investor & Public Relations | N/A | N/A | N/A |
| Mr. Ian J. Watkins | Executive VP & Chief Human Resources Officer | N/A | N/A | 1963 |
| Ms. Silvia Taylor M.B.A. | Executive VP and Chief Corporate Affairs & Advocacy Officer | N/A | N/A | N/A |
Description
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Corporate Governance
Novavax, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 5; Compensation: 5.
